BeOne Medicines (NASDAQ:ONC) Given New $425.00 Price Target at Royal Bank Of Canada

BeOne Medicines (NASDAQ:ONC) had its price objective lifted by Royal Bank Of Canada from $423.00 to $425.00 in a research report report published on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Several other equities analysts have also commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target on the stock in a research note on Monday, January 12th. Wells Fargo & Company initiated coverage on shares of BeOne Medicines in a research note on Monday. They set an “overweight” rating and a $400.00 price objective for the company. Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Truist Financial restated a “buy” rating and issued a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $391.00.

BeOne Medicines Trading Up 1.2%

ONC opened at $317.00 on Thursday. The stock has a fifty day moving average price of $301.40 and a 200-day moving average price of $322.00. The firm has a market cap of $34.78 billion, a price-to-earnings ratio of 70.92 and a beta of 0.50. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22. BeOne Medicines has a 12 month low of $218.31 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.55% and a net margin of 8.94%.The firm had revenue of $1.51 billion during the quarter. As a group, equities research analysts anticipate that BeOne Medicines will post 5.44 earnings per share for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 341 shares of the company’s stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.62% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its holdings in BeOne Medicines by 15.9% during the first quarter. Dimensional Fund Advisors LP now owns 56,879 shares of the company’s stock worth $16,859,000 after acquiring an additional 7,815 shares during the period. Parallel Advisors LLC lifted its holdings in BeOne Medicines by 24.0% in the first quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after acquiring an additional 68 shares during the period. KBC Group NV boosted its position in BeOne Medicines by 5.6% in the 1st quarter. KBC Group NV now owns 9,488 shares of the company’s stock worth $2,818,000 after purchasing an additional 502 shares in the last quarter. SEB Asset Management AB acquired a new stake in shares of BeOne Medicines during the 1st quarter worth approximately $16,653,000. Finally, AIA Group Ltd grew its stake in shares of BeOne Medicines by 15.1% during the 1st quarter. AIA Group Ltd now owns 26,077 shares of the company’s stock worth $7,744,000 after purchasing an additional 3,430 shares during the period. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.